Aptevo Therapeutics Inc.
APVONASDAQHealthcare● Active
$4.89
+$0.17(+3.60%)
Market Cap$10693731
P/E Ratio—
52W High$235.98
52W Low$3.8
Aptevo Therapeutics Inc. (APVO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · APVO · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.01B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | ($0.00B) | ($0.00B) | $0.00B | $0.00B | $0.01B |
| Gross Margin %(computed) | — | — | — | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.01B | $0.01B | $0.02B | $0.02B | $0.02B |
| G&A Expenses | $0.01B | $0.01B | $0.01B | $0.01B | $0.01B |
| Total Operating Expenses | $0.03B | $0.02B | $0.03B | $0.03B | $0.03B |
| Operating Income | ($0.03B) | ($0.02B) | ($0.03B) | ($0.03B) | ($0.02B) |
| Operating Margin %(computed) | — | — | — | -919.75% | -174.10% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.03B) | ($0.02B) | ($0.02B) | $0.01B | ($0.03B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.03B) | ($0.02B) | ($0.02B) | $0.01B | ($0.03B) |
| Net Margin %(computed) | — | — | — | 257.77% | -231.51% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-87.27 | $-31458.00 | $-834044.00 | $922390.00 | $-3557646.00 |
| Wtd Avg Shares | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B |
| EBITDA | ($0.03B) | ($0.02B) | ($0.03B) | ($0.03B) | ($0.02B) |
| EBITDA Margin %(computed) | — | — | — | -890.82% | -164.79% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Aptevo Therapeutics Inc. data
About Aptevo Therapeutics Inc. (APVO) Income Statement
Aptevo Therapeutics Inc. (APVO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, APVO reported revenue of $0.00B, gross profit of ($0.00B) (gross margin —), and net income of ($0.03B) — a net profit margin of —.
Frequently asked questions
APVO · 4 questionsAptevo Therapeutics Inc. (APVO) reported revenue of $0.00B for 2025, down —% year-over-year.
APVO revenueAPVO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09